###begin article-title 0
Histone deacetylase inhibitors: A new mode for inhibition of cholesterol metabolism
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
Eukaryotic gene expression is a complex process involving multiple cis and trans activating molecules to either facilitate or inhibit transcription. In recent years, many studies have focused on the role of acetylation of histone proteins in modulating transcription, whereas deacetylation of these same proteins is associated with inactivation or repression of gene expression. This study explores gene expression in HepG2 and F9 cell lines treated with Trichostatin A (TSA), a potent histone deacetylase inhibitor.
###end p 3
###begin title 4
Results
###end title 4
###begin p 5
###xml 516 523 516 523 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Srebf2 </italic>
These experiments show that TSA treatment results in clear repression of genes involved in the cholesterol biosynthetic pathway as well as other associated pathways including fatty acid biosynthesis and glycolysis. TSA down regulates 9 of 15 genes in this pathway in the F9 embryonal carcinoma model and 11 of 15 pathway genes in the HepG2 cell line. A time course study on the effect of TSA on gene expression of various enzymes and transcription factors involved in these pathways suggests that down regulation of Srebf2 may be the triggering factor for down regulation of the cholesterol biosynthesis pathway.
###end p 5
###begin title 6
Conclusion
###end title 6
###begin p 7
###xml 288 294 <span type="species:ncbi:9606">humans</span>
Our results provide new insights in the effects of histone deacetylases on genes involved in primary metabolism. This observation suggests that TSA, and other related histone deacetylase inhibitors, may be useful as potential therapeutic entities for the control of cholesterol levels in humans.
###end p 7
###begin title 8
Background
###end title 8
###begin p 9
###xml 131 132 131 132 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 232 257 232 257 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Saccharomyces cerevisiae </italic>
###xml 388 389 388 389 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 390 391 390 391 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 511 512 511 512 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 709 710 709 710 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 232 256 <span type="species:ncbi:4932">Saccharomyces cerevisiae</span>
Histone deacetylases (HDACs) are important chromatin remodeling enzymes that are generally involved in transcriptional repression [1]. Mammalian HDACs are classified into three main categories depending on their primary homology to Saccharomyces cerevisiae HDACs (RPD3, HDA1 and SIR2). Histone deacetylase inhibitors (HDACIs) tend to show equal effects on gene activation and repression [2-4]. HDACIs have been shown to induce differentiation, apoptosis or growth arrest in a variety of transformed cell lines [5]. This is generally attributed to the ability of these inhibitors to induce an open chromatin conformation facilitating transcription of regulatory genes like p21 which inhibit tumor cell growth [6]. These qualities make HDACIs promising targets for chemotherapeutic intervention.
###end p 9
###begin p 10
###xml 78 79 78 79 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 170 171 170 171 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 374 375 374 375 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 376 377 376 377 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 437 439 437 439 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 440 442 440 442 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 443 445 443 445 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 472 474 472 474 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 475 477 475 477 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 1111 1113 1111 1113 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 1114 1116 1114 1116 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 1290 1292 1290 1292 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
Recently many different types of HDAC inhibitors have been discovered (Figure 1). These include short chain fatty acids (sodium butyrate, phenylbutyrate, valproic acid) [7], hydroxamic acids (trichostatin A (TSA), suberoylanilide hydromaxic acid (SAHA), pyroxamide, cyclic hydroxamic acid-containing peptides (CHAPs), cinnamic acid bishydroxamic acid (CBHA) and scriptaid) [8,9], cyclic tetrapeptides (trapoxin, apicidin, depsipeptide) [10-13,13], and benzamides (MS-275)[14,15]. Most HDAC inhibitors (HDACIs) developed to date inhibit both Class I and II HDACs equally with the exceptions being valproic acid (5 fold more selective for HDAC1 vs HDACs 5 and 6) and FK-228 (Class I selective). Class I and II HDACs are inhibited by trichostatin A (TSA) and related compounds whereas Class III HDACs are not. As noted, HDACIs have been shown to promote cell cycle arrest, differentiation, and apoptosis in many transformed cultured cell types. In animal models, HDACIs have been shown to inhibit growth of breast, prostate, lung and stomach cancers, as well as neuroblastomas and leukemias, with little toxicity [16,17]. In a previous study looking at the combination regimen of all trans retinoic acid (RA) with the HDACI, Trichostatin A (TSA), we identified several new targets for HDACIs [18]. We also identified critical differences in gene regulation subsequent to treatment with these two agents and a novel promoter module associated with the regulation of a subset of these differentially regulated genes. These analyses focused on the anticancer therapeutic potential of these compounds alone or in combination. Recent analysis of these data identified certain crucial metabolic pathways that have not previously been shown to respond to HDACI treatment and which may be critical in identifying new therapies for cardiovascular health. In this report we discuss the possible role of HDAC inhibition on cholesterol metabolism.
###end p 10
###begin p 11
Structures of common HDAC inhibitors.
###end p 11
###begin title 12
Results
###end title 12
###begin title 13
Microarray results from F9 cell treatments
###end title 13
###begin p 14
###xml 394 395 394 395 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 397 398 397 398 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 416 417 416 417 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S1">1</xref>
###xml 651 657 651 657 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Crabp2</italic>
###xml 659 663 659 663 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Rbp1</italic>
###xml 665 670 665 670 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cyp26</italic>
###xml 694 699 694 699 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H2-Q7</italic>
###xml 701 707 701 707 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H2-Dma</italic>
###xml 709 713 709 713 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H2-L</italic>
###xml 715 721 715 721 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cmkor1</italic>
###xml 723 731 723 731 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H-2D4(q)</italic>
###xml 733 744 733 744 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MHC H-2K-f </italic>
###xml 795 801 795 801 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Col5a1</italic>
###xml 803 810 803 810 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Col13a1</italic>
###xml 812 815 812 815 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Gsn</italic>
###xml 817 822 817 822 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Prhp1</italic>
###xml 824 829 824 829 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Tuba3</italic>
###xml 831 835 831 835 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t-PA</italic>
###xml 837 840 837 840 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cpe</italic>
###xml 842 848 842 848 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Tm4sf6</italic>
###xml 850 856 850 856 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Atp1b2</italic>
###xml 858 862 858 862 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Dsc2</italic>
###xml 919 923 919 923 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cbx4</italic>
###xml 925 929 925 929 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Msx2</italic>
###xml 931 935 931 935 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H1f0</italic>
###xml 937 941 937 941 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Elf3</italic>
###xml 943 947 943 947 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Zfpm</italic>
###xml 971 978 971 978 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Il11ra2</italic>
###xml 980 984 980 984 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PLD1</italic>
###xml 998 1009 998 1009 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cidea, Zac1</italic>
###xml 1036 1042 1036 1042 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IGF-II</italic>
###xml 1044 1050 1044 1050 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Igfbp3</italic>
###xml 1052 1056 1052 1056 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Reck</italic>
###xml 1058 1063 1058 1063 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Meis1</italic>
###xml 1065 1069 1065 1069 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Scgf</italic>
###xml 1099 1105 1099 1105 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Sema3e</italic>
###xml 1107 1116 1107 1116 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Hoxb1 &amp; 4</italic>
###xml 1118 1123 1118 1123 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Stra8</italic>
###xml 1125 1130 1125 1130 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Hoxa1</italic>
###xml 1132 1137 1132 1137 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cdx-1</italic>
###xml 1262 1275 1262 1275 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MMP10, Adam23</italic>
###xml 1306 1311 1306 1311 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Foxd3</italic>
###xml 1313 1317 1313 1317 <italic xmlns:xlink="http://www.w3.org/1999/xlink">UTF1</italic>
###xml 1319 1328 1319 1328 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SF1/Nr5a1</italic>
###xml 1330 1333 1330 1333 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Msc</italic>
###xml 1335 1342 1335 1342 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Mybbp1a</italic>
###xml 1344 1350 1344 1350 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HMGI-C</italic>
###xml 1352 1356 1352 1356 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lyl1</italic>
###xml 1380 1385 1380 1385 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Tdgf1</italic>
###xml 1387 1390 1387 1390 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fst</italic>
###xml 1392 1397 1392 1397 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Gna14</italic>
###xml 1399 1406 1399 1406 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Il12rb2</italic>
###xml 1408 1413 1408 1413 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Il5ra</italic>
###xml 1415 1421 1415 1421 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Map3k4</italic>
###xml 1423 1428 1423 1428 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Vegfc</italic>
###xml 1460 1463 1460 1463 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Myb</italic>
###xml 1465 1470 1465 1470 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Mybl2</italic>
###xml 1472 1476 1472 1476 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Tal1</italic>
###xml 1566 1571 1566 1571 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Dhodh</italic>
###xml 1616 1619 1616 1619 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Mvk</italic>
###xml 1621 1624 1621 1624 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Lss</italic>
###xml 1626 1631 1626 1631 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Hmgcr</italic>
###xml 1633 1646 1633 1646 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fasn and Sqle</italic>
###xml 1656 1657 1656 1657 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
###xml 14 19 <span type="species:ncbi:10090">mouse</span>
###xml 1762 1767 <span type="species:ncbi:10090">mouse</span>
###xml 1834 1839 <span type="species:ncbi:9606">human</span>
###xml 1992 1998 <span type="species:ncbi:9606">humans</span>
Of the 12,451 mouse genes on the Affymetrix MU74Av2 microarray, 1248 genes (upregulated expression of 489 genes and decreased expression of 759 genes) were found to be significantly differentially expressed following TSA treatment. Of these, only 463 genes were found to be differentially expressed at an arbitrary two-fold or greater level of expression (226 genes up; 237 genes down) (Tables 1 &2, Additional file 1). The raw CEL files for the microarray data are available for download at the Gene Expression Omnibus under series GSE1437. Genes for which up regulated expression was noted were involved in retinoid binding and/or metabolism (e.g., Crabp2, Rbp1, Cyp26), the immune response (H2-Q7, H2-Dma, H2-L, Cmkor1, H-2D4(q), MHC H-2K-f class 1 antigen); extracellular matrix regulation (Col5a1, Col13a1, Gsn, Prhp1, Tuba3, t-PA, Cpe, Tm4sf6, Atp1b2, Dsc2); transcription and maintenance of chromatin structure (Cbx4, Msx2, H1f0, Elf3, Zfpm), signal transduction (Il11ra2, PLD1), apoptosis (Cidea, Zac1), cell growth regulation (IGF-II, Igfbp3, Reck, Meis1, Scgf), and embryonic development (Sema3e, Hoxb1 & 4, Stra8, Hoxa1, Cdx-1). Similarly, genes that were down regulated post-TSA treatment included genes involved in extracellular matrix degradation (MMP10, Adam23), transcriptional regulation (Foxd3, UTF1, SF1/Nr5a1, Msc, Mybbp1a, HMGI-C, lyl1), signal transduction (Tdgf1, Fst, Gna14, Il12rb2, Il5ra, Map3k4, Vegfc), and cell cycle deregulation (Myb, Mybl2, Tal1). Interestingly, we also found down regulated genes involved in pyrimidine biosynthesis (Dhodh) and in the cholesterol metabolism pathway (Mvk, Lss, Hmgcr, Fasn and Sqle) (Figure 2). This latter finding was intriguing and we decided to extend our investigations beyond the pluripotent mouse EC cells. These experiments were repeated using the more relevant human hepatocarcinoma derived HepG2 cells, since these are hepatic in origin and the liver is the primary source for cholesterol and fatty acid metabolism in humans. While these are not primary hepatocytes, this cell line offers the ability to both explore the hereto unknown effects of TSA on cholesterol metabolism and also look at the previously known targets of this drug.
###end p 14
###begin p 15
Genes upregulated by TSA treatment in F9 cells (representative genes from total of 226 genes at 2-fold level of expression)
###end p 15
###begin p 16
FC: fold change; Norm: Normalized signal, SE: std error of normalized signal; GB Acc: GeneBank Accession number
###end p 16
###begin p 17
Genes downregulated by TSA treatment in F9 cells (representative genes from total of 237 genes at 2-fold level of expression)
###end p 17
###begin p 18
FC: fold change; Norm: Normalized signal, SE: std error of normalized signal; GB Acc: GeneBank Accession number
###end p 18
###begin p 19
###xml 0 32 0 32 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Map of cholesterol biosynthesis.</bold>
Map of cholesterol biosynthesis. TSA down regulates 9 of 15 genes in this pathway in the F9 embryonal carcinoma model and 11 of 15 pathway genes in the HepG2 cell line.
###end p 19
###begin title 20
Microarray results from HepG2 experiments
###end title 20
###begin p 21
###xml 432 433 432 433 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3</xref>
###xml 611 612 611 612 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 613 614 613 614 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 742 743 742 743 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
###xml 748 749 748 749 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T4">4</xref>
###xml 767 768 767 768 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S1">1</xref>
###xml 952 956 952 956 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pltp</italic>
###xml 1007 1019 1007 1019 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Timp1, Timp2</italic>
###xml 1060 1068 1060 1065 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Tgf&#946;1</italic>
###xml 1166 1170 1163 1167 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Tyms</italic>
###xml 1211 1216 1208 1213 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fthfd</italic>
###xml 1249 1254 1246 1251 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Dhodh</italic>
###xml 1277 1283 1274 1280 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTPSII</italic>
###xml 1453 1457 1450 1454 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ldlr</italic>
###xml 1519 1524 1516 1521 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Acadm</italic>
###xml 1597 1604 1594 1601 <italic xmlns:xlink="http://www.w3.org/1999/xlink">vigilin</italic>
###xml 1661 1667 1658 1664 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Hmgcs1</italic>
###xml 1714 1719 1711 1716 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fdft1</italic>
###xml 1742 1746 1739 1743 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Sqle</italic>
###xml 1807 1813 1804 1810 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Srebf2</italic>
###xml 1851 1856 1848 1853 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Dhcr7</italic>
###xml 1932 1933 1929 1930 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
###xml 14 19 <span type="species:ncbi:9606">human</span>
Of the 54,613 human genes on the Affymetrix HU133 plus 2.0 array, only 6,513 showed significant differential expression following TSA treatment (p value < 0.05). The raw CEL files for the microarray data are available for download at the Gene Expression Omnibus under series GSE4465. TSA treatment of this cell line resulted in 1561 genes being up regulated and 4952 genes being down regulated at this level of significance (Figure 3). This observation was surprising since the current paradigm of HDAC inhibition suggests equal effects on gene activation and repression after treatment with an HDAC inhibitor [3,4]. Furthermore, using a two-fold cutoff, the genelist was reduced to 3229 genes with 254 up and 2975 down regulated (see Tables 3 and 4; Additional file 1) further emphasizing the extreme extent of gene expression down regulation following HDACI treatment. Genes that showed up regulated expression include phospholipid transfer protein (Pltp), tissue inhibitors of metalloproteinase 1 and 2 (Timp1, Timp2) and transforming growth factor beta 1 (Tgfbeta1). Perhaps more importantly, the interesting downregulated genes included thymidylate synthetase (Tyms), formyltetrahydrofolate dehydrogenase (Fthfd), dihydroorotate dehydrogenase (Dhodh) and CTP synthase II (CTPSII) (all of which are related to pyrimidine biosynthesis) as well as genes related to lipid transport and fatty acid metabolism including low density lipoprotein receptor (ldlr), enoyl-Coenzyme A hydratase, acyl-Coenzyme A dehydrogenase (Acadm), apolipoproteins A5, C3, L1, high density lipoprotein binding protein (vigilin); and 3-hydroxy-3-methylglutaryl-Coenzyme A synthase 1 (Hmgcs1), farnesyl-diphosphate farnesyltransferase 1 (Fdft1), squalene epoxidase (Sqle), sterol regulatory element binding transcription factor 2 (Srebf2) and 7-dehydrocholesterol reductase (Dhcr7). Notably 11 of these genes are involved in cholesterol metabolism (Figure 2).
###end p 21
###begin p 22
Genes upregulated by TSA treatment in HEPG2 cells (representative genes from total of 254 genes at 2-fold level of expression)
###end p 22
###begin p 23
FC: fold change; Norm: Normalized signal, SE: std error of normalized signal; GB Acc: GeneBank Accession number
###end p 23
###begin p 24
Genes downregulated by TSA treatment in HEPG2 cells (representative genes from total of 2975 genes at 2-fold level of expression)
###end p 24
###begin p 25
FC: fold change; Norm: Normalized signal, SE: std error of normalized signal; GB Acc: GeneBank Accession number
###end p 25
###begin p 26
###xml 0 225 0 225 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(A)Hierarchical clustering of HepG2 cells treated with ethanol or TSA shows that the majority of genes are down regulated (green) by TSA treatment in contrast with the current paradigm of the role of HDACs in gene repression.</bold>
(A)Hierarchical clustering of HepG2 cells treated with ethanol or TSA shows that the majority of genes are down regulated (green) by TSA treatment in contrast with the current paradigm of the role of HDACs in gene repression. Gene Ontology analysis of the terms related too "biological process" (p-value < 0.05) shows a significant difference in the genes being up-regulated (B) or down-regulated (C) by TSA. The down regulation of metabolic processes includes cholesterol, lipid and fatty acid metabolism.
###end p 26
###begin title 27
Quantitative PCR results
###end title 27
###begin p 28
###xml 234 235 234 235 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4</xref>
###xml 610 611 610 611 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5</xref>
###xml 614 618 614 618 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Hmgc</italic>
###xml 821 827 821 827 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Hmgcs </italic>
###xml 992 996 992 996 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Mvk </italic>
###xml 1011 1018 1011 1018 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Srebf2 </italic>
###xml 1198 1205 1198 1205 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Srebf2 </italic>
###xml 1343 1349 1343 1349 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ApoA5 </italic>
###xml 1353 1359 1353 1359 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Acat2 </italic>
###xml 1469 1475 1469 1475 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ApoL1 </italic>
###xml 1536 1541 1536 1541 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fabp </italic>
###xml 1646 1656 1646 1652 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ppar&#947; </italic>
###xml 1761 1771 1757 1763 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ppar&#947; </italic>
###xml 1888 1896 1880 1888 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cyp27A1 </italic>
###xml 2178 2183 2170 2175 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ldlr </italic>
Sybr green qPCR was used to validate microarray expression data for a subset of the differentially expressed genes. The expression patterns of 10 genes from the F9 microarray data set and 21 from the HepG2 microarray data set (Figure 4) were all confirmed by qPCR. Furthermore we decided to examine the levels of gene expression at early and late time points for 11 of these genes that have a role in cholesterol and lipid metabolism. The relative gene expression was obtained for these genes at 3 h, 6 h, 9 h, 12 h, and 48 h to serve as early and late time frames in comparison to the 24 h treatments (Figure 5). Hmgcr which is the rate limiting enzyme in cholesterol biosynthesis was repressed 2-fold after 12 h of TSA treatment and showed increasing down regulation over 24 h (4 fold) and 48 h (5.3 fold) time points. Hmgcs levels showed increased repression (2.8-3.8 fold) by TSA treatment over 6-24 hours (the amplification reactions failed for the 12 h and 48 h time points). Levels of Mvk (2.1 fold) and Srebf2 (1.8 fold) were down regulated at 3 h with maximal repression at 9 h (13.6 fold and 23.6 fold respectively) after which the levels then came back to normal over the next 39 hours. Srebf2 levels at 6 h, 12 h and 24 h were 2.4 fold, 4.5 fold and 2.4 fold respectively. Genes involved in lipid and fatty acid metabolism such as ApoA5 and Acat2 were found to be maximally down regulated at 12 h (12 fold) and 24 h (16 fold) time points respectively while ApoL1 was down regulated (11 fold) at 12, 24 and 48 h time points. Fabp which is involved in fatty acid metabolism showed increasing down regulation after 12 h (1.9 fold) while Ppargamma was found to be increasingly repressed at 9 h (2.8 fold) followed by reversal after 12 h (3.5 fold). The Ppargamma levels after 48 h of TSA treatment were still almost 2 fold down regulated as compared to untreated cells. Levels of Cyp27A1 or sterol 27-hydroxylase which participates in the conversion of cholesterol to bile acids was also found to be initially down regulated at 6 h (1.8 fold) and increasingly over the 12 (8.8 fold) and 24 h (10.3 fold) time points. TSA treatment did not show any significant effect on Ldlr expression until 24 h (2.8 fold).
###end p 28
###begin p 29
###xml 0 207 0 207 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Real Time qPCR verification of the gene expression levels of various genes involved in (A) lipid transport and fatty acid synthesis, (B) cholesterol metabolism and (C) pyrimidine biosynthesis in HepG2 cells.</bold>
Real Time qPCR verification of the gene expression levels of various genes involved in (A) lipid transport and fatty acid synthesis, (B) cholesterol metabolism and (C) pyrimidine biosynthesis in HepG2 cells. Fold expression is relative to ethanol control. TSA treatment showed down regulated expression of 14 genes by both qPCR and microarray.
###end p 29
###begin p 30
###xml 0 105 0 105 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Time course of gene expression in response to TSA treatment of HepG2 cells for 3, 6, 9, 12, 24 and 48 h. </bold>
Time course of gene expression in response to TSA treatment of HepG2 cells for 3, 6, 9, 12, 24 and 48 h. Values are represented as fold change relative to ethanol treated controls at the respective time points.
###end p 30
###begin title 31
Discussion
###end title 31
###begin p 32
###xml 184 186 184 186 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 660 665 660 665 <italic xmlns:xlink="http://www.w3.org/1999/xlink">dhodh</italic>
###xml 802 804 802 804 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 805 807 805 807 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 810 816 810 816 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Dhodh </italic>
###xml 982 984 982 984 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 1138 1140 1138 1140 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 1548 1550 1548 1550 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 1718 1720 1714 1716 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 1958 1964 1954 1960 <italic xmlns:xlink="http://www.w3.org/1999/xlink">dhodh </italic>
###xml 2200 2204 2196 2200 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Tyms</italic>
###xml 2494 2507 2490 2503 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MMP-1, MMP-13</italic>
###xml 2548 2576 2544 2572 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Adamts4, Adamts5 and Adamts9</italic>
###xml 2579 2581 2575 2577 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 2766 2794 2762 2790 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MMP-1, MMP-2, MMP-11, MMP-12</italic>
###xml 2815 2823 2811 2819 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Adamts9 </italic>
###xml 2939 2951 2935 2947 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TIMP1, TIMP2</italic>
###xml 3096 3105 3092 3097 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNF&#945; </italic>
###xml 3161 3167 3153 3159 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL-12 </italic>
###xml 3171 3176 3163 3168 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL-8 </italic>
###xml 3256 3261 3248 3253 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al</italic>
###xml 3264 3266 3256 3258 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 704 710 <span type="species:ncbi:10090">murine</span>
###xml 760 765 <span type="species:ncbi:9606">human</span>
###xml 1396 1399 <span type="species:ncbi:10116">rat</span>
###xml 2133 2137 <span type="species:ncbi:10090">mice</span>
###xml 2142 2145 <span type="species:ncbi:9606">men</span>
###xml 3360 3364 <span type="species:ncbi:10090">mice</span>
###xml 3369 3374 <span type="species:ncbi:9606">human</span>
In a previous study we had used microarray analyses to examine the effects of RA and TSA on embryonal carcinoma cell growth and differentiation using the prototypical EC cell line F9 [18]. Results from these studies identified several important genes and pathways differentially regulated by these compounds. In this report we identify new target pathways for TSA treatment based on further analysis of this data. Most importantly, the regulatory pathways that are affected include pyrimidine metabolism and cholesterol biosynthesis. The pyrimidine pathway is of interest because one of the rate limiting enzymes in this pathway, dihydroorotate dehydrogenase (dhodh), has been targeted for inhibition in murine models of rheumatoid arthritis as well as in the human T-lymphoblastoma cell line (A3.01) [21,22]. Dhodh catalyzes the fourth committed step in the de novo biosynthesis of pyrimidines. Activated lymphocytes expand their pyrimidine pool by eightfold during proliferation [23]. In rheumatoid arthritis, inflammation and degradation of synovial tissue are initiated by the influx of lymphocytes (B cells, CD4+, CD8+ and T cells) [24]. Thus, inhibiting activated T-cells by decreasing their supply of pyrimidines via TSA treatment could provide an attractive alternative method for treating rheumatoid arthritis. Interestingly, HDACIs (TSA and phenylbutyrate) were used as treatments in a rat model of rheumatoid arthritis, and resulted in reduced inflammation, and inhibition both of synovial hyperplasia and bone or cartilage destruction [25]. The authors also found that HDACIs inhibited the expression of tumor necrosis factor-alpha, which functions to stimulate matrix degradation in rheumatoid arthritis [26], therefore suggesting a mechanism by which HDACIs may alleviate some effects of rheumatoid arthritis. Further extending and supporting these results, in this study, we found that TSA itself could significantly inhibit the expression of dhodh even in non-lymphatic cells (60% in F9 and 25% in HepG2), providing an alternative (or synergistic) mechanism by which HDACI might suppress rheumatoid arthritis in both mice and men. Moreover, the mRNA levels of thymidylate synthetase (Tyms), another key enzyme in this pathway, were decreased 8 fold in HepG2 cells (2.4 fold in F9 cells) further potentiating this effect of TSA treatment. A previous study using chondrocytes showed that HDACIs such as TSA and sodium butyrate, blocked the induction of matrix metalloproteinases (MMP-1, MMP-13) as well as aggrecan-degrading enzymes (Adamts4, Adamts5 and Adamts9) [27]. Both of these enzyme families mediate cartilage destruction. In our study with HepG2 cells, we also found that TSA treatment resulted in a modest decrease in the expression of MMPs (MMP-1, MMP-2, MMP-11, MMP-12) (1.2-1.5 fold) and Adamts9 (1.6 fold). This, coupled with increased expression (2.8 fold) of a collagenase inhibitor (tissue inhibitor of MMP: TIMP1, TIMP2), might further promote maintenance of a growth regulating matrix. Interestingly, TSA treatment also resulted in down regulation of LPS induced TNFalpha levels (2 fold) as well as suppression of the cytokines IL-12 and IL-8 (2.7 and 2 fold respectively). This result is consistent with a report by Leoni et al. [28] on the anti-inflammatory properties of SAHA (another hydroxamic acid based HDACI) in Balb/c mice and human PBMCs induced with LPS.
###end p 32
###begin p 33
###xml 451 453 451 453 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 859 864 859 864 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Hmgcr</italic>
###xml 886 889 886 889 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Mvk</italic>
###xml 923 926 923 926 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Mvd</italic>
###xml 955 959 955 959 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Idi1</italic>
###xml 983 988 983 988 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fdft1</italic>
###xml 1011 1015 1011 1015 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Sqle</italic>
###xml 1039 1041 1039 1041 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ls</italic>
###xml 1068 1074 1068 1074 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Sc4mol</italic>
###xml 1120 1125 1120 1125 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Nsdhl</italic>
###xml 1135 1136 1135 1136 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
###xml 1177 1182 1177 1182 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Hmgcr</italic>
###xml 1184 1187 1184 1187 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Mvd</italic>
###xml 1189 1193 1189 1193 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Idi1</italic>
###xml 1195 1199 1195 1199 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Sqle</italic>
###xml 1201 1204 1201 1204 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Lss</italic>
###xml 1206 1213 1206 1213 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Sc4mol </italic>
###xml 1217 1222 1217 1222 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Nsdhl</italic>
###xml 1301 1302 1301 1302 <italic xmlns:xlink="http://www.w3.org/1999/xlink">z</italic>
###xml 1472 1473 1472 1473 <italic xmlns:xlink="http://www.w3.org/1999/xlink">z</italic>
###xml 2060 2075 2060 2075 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Hmgcr, Mvd, Lss</italic>
###xml 2123 2127 2123 2127 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Mvd </italic>
###xml 2131 2135 2131 2135 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Lss </italic>
The pathway most significantly affected by TSA treatment in F9 EC cells is that of cholesterol biosynthesis, most specifically those steps involved in the synthesis of low density lipoprotein. There are two main types of lipoproteins that transport cholesterol in the blood: low density lipoproteins (LDL) and high density lipoproteins (HDL). HDL particles are generally considered to be "good cholesterol", while LDL is considered "bad cholesterol" [29]. Several genes encoding essential enzymes in the LDL synthesis pathway are down regulated by these treatments. Pathway analysis of microarray data using genes showing statistically significant (p < 0.05) differential gene expression indicated that expression levels of 9 enzymes out of the 15 in the cholesterol biosynthesis pathway are decreased following TSA treatment. They include HMG CoA reductase (Hmgcr), mevalonate kinase (Mvk), di-p-mevalonate decarboxylase (Mvd), isopentenyl-PP isomerase (Idi1), squalene synthatase (Fdft1), squalene epoxidase (Sqle), lanosterol synthase (Lss) and lanosterol oxidase (Sc4mol) and NAD(P)-dependent steroid dehydrogenase (Nsdhl) (Figure 2). Of these only 6 of these 9, including Hmgcr, Mvd, Idi1, Sqle, Lss, Sc4mol and Nsdhl, showed a greater than two fold differential expression on TSA treatment. The z-score assigned to each category by MAPPFinder reflects the degree to which the expression of genes in that category was greater than that expected by chance. A positive z-score indicates that a large number of genes in that category are differentially expressed between the compared conditions while a negative Z score indicates that the there are fewer genes meeting the criterion than would be expected by random chance. If the MAPPFinder data truly obeyed the assumptions of the hypergeometric distribution, then a Z score or 1.96 or -1.96 would correlate with a p value of 0.05. The z-score for this pathway was highly significant with values of 4.85 associated with TSA treatment. Real-time qPCR analyses verified decreased expression of 3 of 5 genes (Hmgcr, Mvd, Lss) in this pathway but the expression of neither Mvd nor Lss was significantly down regulated by TSA. Decreasing high cholesterol levels using TSA treatments may work well since repression of few of the detected genes may be sufficient to induce the response, i.e., a reduction in cholesterol intermediates and synthesis.
###end p 33
###begin p 34
###xml 647 648 647 648 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3</xref>
###xml 772 778 772 778 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Hmgcs1</italic>
###xml 800 805 800 805 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Hmgcr</italic>
###xml 842 848 842 848 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Srebf2</italic>
###xml 887 894 883 890 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cyp51a1</italic>
###xml 976 980 972 976 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fasn</italic>
###xml 1011 1015 1007 1011 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fabp</italic>
###xml 1049 1053 1045 1049 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fdps</italic>
###xml 1080 1085 1076 1081 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Acaca</italic>
###xml 1114 1119 1110 1115 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Acadm</italic>
###xml 1153 1158 1149 1154 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Acat2</italic>
###xml 1213 1222 1209 1214 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ppar&#947;</italic>
###xml 1393 1467 1385 1459 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Hmgcr, Hmgcs1, Srebf2, Fabp Fasn, Fdps, Acaca, Acadm, Acat2, ApoA5, C1, E </italic>
###xml 1471 1474 1463 1466 <italic xmlns:xlink="http://www.w3.org/1999/xlink">L1 </italic>
###xml 1485 1492 1477 1484 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cyp27a1</italic>
###xml 1494 1498 1486 1490 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ldlr</italic>
###xml 1500 1519 1492 1507 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ppar&#947; and Tyms </italic>
###xml 1527 1528 1515 1516 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4</xref>
###xml 1689 1696 1677 1684 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Srebf2 </italic>
###xml 1783 1789 1771 1777 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Hmgcr </italic>
###xml 1836 1839 1824 1827 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Mvd</italic>
###xml 1858 1865 1846 1853 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Srebf2 </italic>
###xml 1961 1968 1949 1956 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Srebf2 </italic>
###xml 2022 2024 2010 2012 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 2200 2207 2188 2195 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Srebf2 </italic>
###xml 2427 2433 2415 2421 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Hmgcs </italic>
###xml 2453 2459 2441 2447 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Hmgcr </italic>
###xml 2483 2488 2471 2476 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ldlr </italic>
###xml 2547 2549 2535 2537 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 2552 2561 2540 2549 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Srebf-1a </italic>
###xml 2566 2569 2554 2557 <italic xmlns:xlink="http://www.w3.org/1999/xlink">1c </italic>
###xml 2644 2646 2632 2634 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 2647 2649 2635 2637 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 2697 2704 2685 2692 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Srebf1 </italic>
###xml 2863 2867 2851 2855 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Idh1</italic>
###xml 3002 3007 2990 2995 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Idh1 </italic>
###xml 3032 3040 3020 3028 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Srebf1a </italic>
###xml 3044 3051 3032 3039 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Srebf2 </italic>
###xml 3076 3078 3064 3066 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 3181 3189 3169 3177 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cyp51a1 </italic>
###xml 3387 3389 3371 3373 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 3434 3442 3418 3426 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cyp51a1 </italic>
###xml 153 158 <span type="species:ncbi:9606">human</span>
###xml 3054 3059 <span type="species:ncbi:9606">human</span>
Following the analysis of these pluripotent EC cells, we decided to investigate these effects in the HepG2 cell line which arose from a carcinoma of the human liver, the primary organ for cholesterol and fatty acid metabolic processes. While we realize that primary hepatocytes would be a better model to evaluate this pathway, we choose the HepG2 cell line as an means to evaluate this phenomenon but allowing for use of the known anti-cancer effects of TSA as a control. Expression data from HepG2 cells also indicated that multiple enzymes in cholesterol biosynthesis and fatty acid synthesis pathways were significantly down regulated (Figure 3). The mRNA transcript levels that were repressed at a greater than 2 fold level of significance included HMG CoA synthase (Hmgcs1), HMG CoA reductase (Hmgcr), sterol receptor binding factor-2 (Srebf2) and lanosterol 14 alpha-demethylase (Cyp51a1) (involved in cholesterol metabolism), and others including fatty acid synthase (Fasn), fatty acid binding protein (Fabp), farnesyl diphosphate synthase (Fdps), acetyl-coA carboxylase (Acaca), acetyl-coA dehydrogenase (Acadm), acetyl-coA acetyl transferase (Acat2), peroxisome proliferative activated receptor, gamma (Ppargamma) and a variety of apolipoproteins that are involved in fatty acid and triglyceride metabolism. Quantitative PCR studies verified that TSA treatment reduced expression of Hmgcr, Hmgcs1, Srebf2, Fabp Fasn, Fdps, Acaca, Acadm, Acat2, ApoA5, C1, E and L1 as well as Cyp27a1, Ldlr, Ppargamma and Tyms (Figure 4). The down regulation seems to be a complex phenomenon involving genes that regulate these pathways at different levels. Most evident is the down regulation of Srebf2 which in turn acts as a transcription factor regulating the expression of enzymes like Hmgcr (the target for the statin class of drugs) and Mvd. It is known that Srebf2 overexpression induces all 12 enzymes in the cholesterol biosynthesis pathway and inhibition of Srebf2 by TSA might inhibit the expression of these enzymes [30]. In fact, our microarray data demonstrates that the levels of almost all these enzymes are down (10 genes pass all cutoff filters) following TSA treatment. The repression of Srebf2 occurs at a early time point (around 3 hrs) and continually repressed over 24 hrs (2.4 fold repression at 24 h). This effect is probably responsible for the down regulation of the cholesterol pathway since expression of Hmgcs (repressed at 6 h), Hmgcr (repressed at 12 h) and Ldlr (repressed at 24 h) are all known to be induced by Srebf2 [31]. Srebf-1a and -1c are more involved with regulation of fatty acid synthesis and lipogenesis [30,32]. While we were unable to detect the levels of Srebf1 expression in our microarray experiments, TSA treatment modestly (1.3 fold) decreased expression levels of cytosolic NADP-dependent isocitrate dehydrogenase1 (Idh1) which provides the cytosolic NADPH required for proper functioning of both the cholesterol and fatty acid biosynthetic pathways. The Idh1 promoter is activated by Srebf1a and Srebf2 in human hepatoma cells [33]. Thus there appears to be a concerted down regulation of both pathways through a synergistic effect. Cyp51a1 (lanosterol 14alpha-demethylase) is another important intermediate in cholesterol metabolism and has in recent years gained importance as a target for the development of hypocholesterolemic agents [34]. Our microarray data showed that levels of Cyp51a1 were also down regulated further adding support to the possible use of this HDACI as a way to decrease plasma cholesterol levels.
###end p 34
###begin p 35
###xml 97 99 97 99 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 299 301 299 301 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 467 469 467 469 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 470 472 470 472 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
###xml 652 654 652 654 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
###xml 723 725 723 725 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B40">40</xref>
###xml 840 845 840 845 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ldlr </italic>
###xml 883 889 883 889 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Srebf2</italic>
###xml 939 946 939 946 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Srebf2 </italic>
###xml 1031 1039 1031 1039 <italic xmlns:xlink="http://www.w3.org/1999/xlink">de novo </italic>
###xml 1222 1227 1222 1227 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pcsk9</italic>
###xml 1251 1253 1251 1253 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B41">41</xref>
###xml 1307 1312 1307 1312 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ldlr </italic>
###xml 1385 1391 1385 1391 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pcsk9 </italic>
###xml 1611 1616 1611 1616 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ldlr </italic>
###xml 1677 1684 1677 1684 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Srebf2 </italic>
Finally, atherosclerosis is the underlying disorder associated with most cardiovascular disease [35]. This disorder is characterized by deposits of fatty substances, cholesterol, cellular waste products, calcium and other substances in the inner lining of an artery (collectively known as plaques) [36]. Cholesterol has been implicated as the major contributor to this condition as atherosclerosis is strongly correlated with an increase in serum cholesterol levels [37,38]. Generally, serum levels should be between 140 and 200 mg per deciliter (mg/dl) whereas high levels surpassing 240 mg/dl indicate one is at high risk for cardiovascular disease [39]. Thus, atherosclerosis is characterized by elevated levels of LDL [40]. The activity of the hepatic LDL receptor (Ldlr) is the primary determinant of plasma LDL cholesterol levels and Ldlr transcription is in turn regulated by Srebf2. When the levels of hepatocellular sterols drop, Srebf2 is activated and this process restores the normal levels by concurrent activation of de novo cholesterol synthesis and increased uptake of plasma cholesterol through Ldlr. LDL receptor is also post transcriptionally regulated by proprotein convertase subtilisn/kexin type 9a (Pcsk9) in an inverse manner [41]. While our microarray and qPCR data shows decreased Ldlr expression following TSA treatment, microarray gene expression levels of Pcsk9 are also down regulated. This suggests existence of a mechanism for potential compensatory increase in Ldlr levels or activity post-transcriptionally. Our time course experiments did not show a significant repression of Ldlr levels until 24 h further highlighting the complex nature of Srebf2 regulation.
###end p 35
###begin p 36
###xml 127 165 127 165 <italic xmlns:xlink="http://www.w3.org/1999/xlink">apoA1, apoA5, apoB, apoC1, apoE, apoL1</italic>
###xml 651 653 651 653 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B42">42</xref>
###xml 654 656 654 656 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B43">43</xref>
###xml 886 888 886 888 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B44">44</xref>
###xml 891 897 891 897 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Acat2 </italic>
###xml 989 999 989 999 <italic xmlns:xlink="http://www.w3.org/1999/xlink">apoB-Ldlr </italic>
###xml 1009 1011 1009 1011 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B45">45</xref>
###xml 1271 1282 1271 1282 <italic xmlns:xlink="http://www.w3.org/1999/xlink">apoB, apoE </italic>
###xml 1286 1292 1286 1292 <italic xmlns:xlink="http://www.w3.org/1999/xlink">apoA1 </italic>
###xml 1327 1348 1327 1348 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Acat2, Fasn and Hmga2</italic>
###xml 1549 1553 1549 1553 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cyp2</italic>
###xml 1632 1642 1632 1638 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPAR&#947; </italic>
###xml 1750 1758 1746 1754 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cyp27a1 </italic>
###xml 1791 1801 1787 1793 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ppar&#947; </italic>
###xml 679 683 <span type="species:ncbi:10090">mice</span>
###xml 762 766 <span type="species:ncbi:10090">mice</span>
###xml 1003 1007 <span type="species:ncbi:10090">mice</span>
Our data with TSA treatment also showed a decrease in the levels of gene expression for a variety of apolipoproteins including apoA1, apoA5, apoB, apoC1, apoE, apoL1. This observation highlights the complex relationship of apolipoprotein levels and lipoprotein metabolism. While elevated levels of apoB and reduced levels of apoA1 are associated with increased cardiac disease, serum levels of apoB100 associated VLDL are regulated in turn by Acat2 which stimulates cholesteryl ester secretion into apoB-containing lipoproteins. Acat inhibitors are being developed as a therapeutic means to lower LDL cholesterol without affecting cholesterol uptake [42,43]. Also apoE deficient mice show high levels of cholesterol and develop spontaneous atherosclerosis while mice with partial or complete deficiency of high-mobility group A2 protein (Hmga2) are able to resist diet-induced obesity [44]. Acat2 inhibition using antisense nucleotides was previously shown to alleviate atherosclerosis in apoB-Ldlr -/- mice [45]. This study also found Acat2 inhibition to be effective in reducing plasma cholesterol, increasing plasma triglycerides, and shifting LDL cholesteryl ester fatty acids to become mainly polyunsaturated. In our study, TSA treatment showed a modest decrease in apoB, apoE and apoA1 in addition to decreased levels of Acat2, Fasn and Hmga2. This indicates that triglyceride metabolism is perturbed by TSA and further studies may be necessary to evaluate the possibility of using TSA and other HDACIs for modulating triglyceride metabolism. Cyp27 has been reported to be regulated by the nuclear receptor subfamily of which PPARgamma is a member and levels of both these genes have been found to be high in atherosclerotic lesions. Levels of Cyp27a1 (maximal repression at 24 h) and Ppargamma (maximal repression between 9-12 h) were found to be repressed by TSA treatment in both the microarray and qPCR data. This observation adds credence to the potential for development of TSA like HDACIs for atherosclerosis.
###end p 36
###begin title 37
Conclusion
###end title 37
###begin p 38
Our results show that cholesterol metabolism is significantly down regulated by TSA both directly and indirectly and thus HDACI therapy may be a relatively novel tool to develop for use in controlling cholesterol levels. This study only addresses the effect of TSA treatment on transcript levels of the rate limiting enzymes and transcription factors and further studies evaluating protein expression levels are necessary to derive firm conclusions on regulation of this pathway. Additional studies exploring the different classes of HDACIs with respect to their effects on regulation of the genes in the cholesterol pathway would also help dissect the details of this innovative application for these drugs.
###end p 38
###begin title 39
Methods
###end title 39
###begin title 40
Cell Culture for Microarray and Quantitative PCR Analysis
###end title 40
###begin p 41
###xml 74 76 74 76 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 275 277 275 277 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6 </sup>
###xml 288 290 288 290 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 3 8 <span type="species:ncbi:10090">mouse</span>
F9 mouse embryonal carcinoma cells were cultured as published previously [18] Stock solutions of TSA (3 mM) (Sigma-Aldrich) were freshly prepared in absolute ethanol for each experiment and were diluted in DMEM to a final concentration of 70 nM. Cells were seeded at 2.5 x 106 cells/75 cm2 gelatinized flask and treated with ethanol or TSA for 24 h. All experiments were performed in triplicate using a different preparation of F9 cells for each experiment.
###end p 41
###begin p 42
###xml 17 22 <span type="species:ncbi:9606">human</span>
Similarly, HepG2 human hepatoma cells were cultured using DMEM containing 10% FBS and treated with TSA (0.35 muM) or an ethanol control (final concentration 0.2%) for 24 hours before being harvested for RNA isolation. For time course experiments, total RNA was isolated from HepG2 cells treated with an ethanol control or 0.35 muM TSA for 3, 6, 9, 12, 24 or 48 h.
###end p 42
###begin title 43
RNA extraction and purification
###end title 43
###begin p 44
Both F9 and HepG2 cells were harvested with 4 mL of Tri-reagent (Molecular Research Center, Inc) and RNA isolation was carried out according to the manufacturer's protocol. Total RNA was purified using the RNeasy cleanup kit and protocol (Qiagen), quantified and then analyzed for degradation on a BioAnalyzer (Agilent).
###end p 44
###begin title 45
Hybridization of sample to GeneChip Microarrays
###end title 45
###begin p 46
RNA was converted to biotinylated cRNA (complimentary RNA) from oligo-dT-primed cDNA using standard Affymetrix protocols. Biotinylated cRNA was used to probe the MU74Av2 (F9 samples) or HU133 Plus 2.0 (HepG2 samples) Affymetrix GeneChip microarrays. A total of six samples (three controls and three TSA treated) for each cell line were analyzed.
###end p 46
###begin title 47
Statistical Analysis
###end title 47
###begin p 48
###xml 394 397 394 397 <sup xmlns:xlink="http://www.w3.org/1999/xlink">th </sup>
The raw data (CEL files) were imported into GeneSpring software (v7.2) for further analysis. A two-step normalization algorithm was implemented to select differential gene expression in response to TSA samples (ethanol treated samples as baseline). In the first normalization step, a global scaling per chip method was used in which the signal of each gene was divided by the mean intensity (50th percentile) of the chip. This normalization step was followed by a per gene normalization which divides each gene by the average intensity of that gene in several control samples. Hierarchical clustering was used to organize the data in discrete expression profiles. Selection of statistically significant genes from each expression profile was done using a p-value cut off of </= 0.05 with the cross gene error model (CGEM) combined with Welch t-test. The multiple testing correction (Benjamini and Hochberg false discovery rate) was integrated within each test. Additionally we also analyzed the HepG2 data using both MAS5 (Microarray Suite) as well as RMA (Robust Microarray Analysis) algorithms and genes that passed all criteria from both sets of analyses were used for follow up studies.
###end p 48
###begin title 49
Pathway and Functional Cluster Analysis
###end title 49
###begin p 50
###xml 194 196 194 196 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 197 199 197 199 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
The differentially expressed genes selected as described above were subjected to functional cluster analysis using MAPPFinder in conjunction with GenMAPP (Gene Microarray Pathway Profiler) 2.0 [19,20]
###end p 50
###begin title 51
Quantitative Real-Time PCR
###end title 51
###begin p 52
###xml 1122 1123 1102 1103 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T5">5</xref>
To verify the data obtained from microarrays, 5 mug of total RNA was taken from the same pool of RNA as used for the microarray experiments. The RNA was DNase treated (Ambion) and reverse transcribed to cDNA which served as the template for quantitative PCR (qPCR). Real-time relative qPCR (SYBR Green; Applied Biosystems) was performed in triplicate using a GeneAmp 5700 (F9 samples) or a HT7900 sequence detection system (HepG2 samples) according to the manufacturer's instructions. Primers were specifically designed using Primer express software (Applied Biosystems). 1 mug of cDNA was amplified in 1x SYBR green buffer. PCR conditions were: 10 min at 95degreesC for AmpliTaq Gold DNA polymerase activation, 45 thermal cycles of 15 sec at 95degreesC to denature and 1 min at 60degreesC to anneal and extend. Relative expression levels were analyzed using the  method using the GAPDH expression level as a control. Samples treated with TSA were compared to the baseline expression value determined from ethanol treated samples at the respective time points and the fold change is shown. (For primer sequences see Table 5).
###end p 52
###begin p 53
Primers used for Sybr green qPCR
###end p 53
###begin p 54
###xml 40 42 40 42 <sub xmlns:xlink="http://www.w3.org/1999/xlink">T </sub>
###xml 102 107 102 107 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GAPDH</italic>
###xml 136 138 128 130 <sub xmlns:xlink="http://www.w3.org/1999/xlink">T </sub>
For quantitative analysis of the data, CT (threshold-cycle number) values were normalized to those of GAPDH, with use of the DeltaDeltaCT method.
###end p 54
###begin title 55
Authors' contributions
###end title 55
###begin p 56
SVC conceived the study design for the HepG2 samples and conducted all the analysis for this paper. NSG performed the microarray study on the F9 samples under the guidance of PJM.
###end p 56
###begin title 57
Supplementary Material
###end title 57
###begin title 58
Additional file 1
###end title 58
###begin p 59
###xml 0 140 0 140 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Full list of statistically significant (p &lt; 0.05) genes differentially expressed (2-fold or greater) in F9 and HepG2 cells on TSA treatment.</bold>
Full list of statistically significant (p < 0.05) genes differentially expressed (2-fold or greater) in F9 and HepG2 cells on TSA treatment.
###end p 59
###begin p 60
Click here for file
###end p 60
###begin title 61
Acknowledgements
###end title 61
###begin p 62
We would like to acknowledge Marcy Kuentzel and David Frank for help with the experiments and to Dr. Martin Tenniswood for his valuable suggestions.
###end p 62
###begin article-title 63
Histone deacetylase inhibitors
###end article-title 63
###begin article-title 64
###xml 68 73 <span type="species:ncbi:9606">human</span>
Histone deacetylase inhibitors profoundly decrease proliferation of human lymphoid cancer cell lines
###end article-title 64
###begin article-title 65
Microarray analysis of differentiation-specific gene expression during 3T3-L1 adipogenesis
###end article-title 65
###begin article-title 66
###xml 34 39 <span type="species:ncbi:9606">human</span>
Epigenetics of gene expression in human hepatoma cells: expression profiling the response to inhibition of DNA methylation and histone deacetylation
###end article-title 66
###begin article-title 67
Histone deacetylase inhibitors
###end article-title 67
###begin article-title 68
Histone deacetylase inhibitors: biology and mechanism of action
###end article-title 68
###begin article-title 69
Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells
###end article-title 69
###begin article-title 70
Histone deacetylase inhibitors: from target to clinical trials
###end article-title 70
###begin article-title 71
Histone deacetylase as a new target for cancer chemotherapy
###end article-title 71
###begin article-title 72
Trapoxin, an antitumor cyclic tetrapeptide, is an irreversible inhibitor of mammalian histone deacetylase
###end article-title 72
###begin article-title 73
Trichostatin A and trapoxin: novel chemical probes for the role of histone acetylation in chromatin structure and function
###end article-title 73
###begin article-title 74
Apicidin, an inhibitor of histone deacetylase, prevents H-ras-induced invasive phenotype
###end article-title 74
###begin article-title 75
FR90 a potent antitumor antibiotic, is a novel histone deacetylase inhibitor
###end article-title 75
###begin article-title 76
Synthesis and histone deacetylase inhibitory activity of new benzamide derivatives
###end article-title 76
###begin article-title 77
###xml 104 109 <span type="species:ncbi:9606">human</span>
A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors
###end article-title 77
###begin article-title 78
###xml 94 99 <span type="species:ncbi:10090">mouse</span>
Inhibition of histone deacetylase activity by trichostatin A modulates gene expression during mouse embryogenesis without apparent toxicity
###end article-title 78
###begin article-title 79
Histone deacetylases and cancer: causes and therapies
###end article-title 79
###begin article-title 80
Molecular profiling of embryonal carcinoma cells following retinoic acid or histone deacetylase inhibitor treatment
###end article-title 80
###begin article-title 81
MAPPFinder: using Gene Ontology and GenMAPP to create a global gene-expression profile from microarray data
###end article-title 81
###begin article-title 82
GenMAPP, a new tool for viewing and analyzing microarray data on biological pathways
###end article-title 82
###begin article-title 83
Dihydroorotate dehydrogenase is a high affinity binding protein for A77 1726 and mediator of a range of biological effects of the immunomodulatory compound
###end article-title 83
###begin article-title 84
Inhibition of dihydroorotate dehydrogenase by the immunosuppressive agent leflunomide
###end article-title 84
###begin article-title 85
###xml 86 92 <span type="species:ncbi:9606">humans</span>
Importance of ribonucleotide availability to proliferating T-lymphocytes from healthy humans. Disproportionate expansion of pyrimidine pools and contrasting effects of de novo synthesis inhibitors
###end article-title 85
###begin article-title 86
New insights in the pathogenesis of rheumatoid arthritis
###end article-title 86
###begin article-title 87
A therapeutic strategy uses histone deacetylase inhibitors to modulate the expression of genes involved in the pathogenesis of rheumatoid arthritis
###end article-title 87
###begin article-title 88
Inhibition of the production and effects of interleukin-1 and tumor necrosis factor alpha in rheumatoid arthritis
###end article-title 88
###begin article-title 89
Histone deacetylase inhibitors modulate metalloproteinase gene expression in chondrocytes and block cartilage resorption
###end article-title 89
###begin article-title 90
The antitumor histone deacetylase inhibitor suberoylanilide hydroxamic acid exhibits antiinflammatory properties via suppression of cytokines
###end article-title 90
###begin article-title 91
Coronary atherosclerosis and plasma lipoproteins: epidemiology and pathophysiologic considerations
###end article-title 91
###begin article-title 92
Sterol regulatory element-binding proteins induce an entire pathway of cholesterol synthesis
###end article-title 92
###begin article-title 93
The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor
###end article-title 93
###begin article-title 94
Acetyl-coenzyme A synthetase is a lipogenic enzyme controlled by SREBP-1 and energy status
###end article-title 94
###begin article-title 95
###xml 85 90 <span type="species:ncbi:9606">human</span>
IDH1 gene transcription is sterol regulated and activated by SREBP-1a and SREBP-2 in human hepatoma HepG2 cells: evidence that IDH1 may regulate lipogenesis in hepatic cells
###end article-title 95
###begin article-title 96
###xml 75 80 <span type="species:ncbi:9606">human</span>
Three-dimensional quantitative structure-activity relationship analysis of human CYP51 inhibitors
###end article-title 96
###begin article-title 97
The future of best practice
###end article-title 97
###begin article-title 98
The pathogenesis of atherosclerosis: atherogenesis and inflammation
###end article-title 98
###begin article-title 99
###xml 71 74 <span type="species:ncbi:9606">men</span>
Serum cholesterol levels and six-year mortality from stroke in 350,977 men screened for the multiple risk factor intervention trial
###end article-title 99
###begin article-title 100
Serum cholesterol, lipoproteins, and the risk of coronary heart disease. The Framingham study
###end article-title 100
###begin article-title 101
Significance of cholesterol in health and disease
###end article-title 101
###begin article-title 102
###xml 27 30 <span type="species:ncbi:9606">men</span>
Serum cholesterol in young men and subsequent cardiovascular disease
###end article-title 102
###begin article-title 103
###xml 64 68 <span type="species:ncbi:10090">mice</span>
Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9
###end article-title 103
###begin article-title 104
###xml 109 130 <span type="species:ncbi:9534">African green monkeys</span>
ACAT inhibitors CL 283,546 and CL 283,796 reduce LDL cholesterol without affecting cholesterol absorption in African green monkeys
###end article-title 104
###begin article-title 105
ACAT2 is a target for treatment of coronary heart disease associated with hypercholesterolemia
###end article-title 105
###begin article-title 106
Histone deacetylase inhibition is associated with transcriptional repression of the Hmga2 gene
###end article-title 106
###begin article-title 107
###xml 110 114 <span type="species:ncbi:10090">mice</span>
Dietary fat-induced alterations in atherosclerosis are abolished by ACAT2-deficiency in ApoB100 only, LDLr-/- mice
###end article-title 107

